Latest:
Dr Tagawa on the Evaluation of Lutetium Lu 177 Rospatamab Tetraxetan Plus SOC in mCRPC
Scott T. Tagawa, MD, FASCO, FACP, MS, discusses the addition of lutetium 177Lu-rosopatamab tetraxetan to SOC in mCRPC.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Arutha Kulasinghe, PhD
Latest:
Dr Kulasinghe on a Study Profiling the NSCLC Tumor Microenvironment
Arutha Kulasinghe, PhD, discusses findings from a study profiling the tumor microenvironment of non–small cell lung cancer, as well as future directions planned with this research and the implications of these findings.
Alissa J. Cooper, MD
Latest:
Final Thoughts and Clinical Pearls for Treating SCLC
Panelists discuss how the next 3 to 5 years will likely see T-cell engagers moving into earlier treatment lines, potential ADCs replacing chemotherapy in first-line therapy, and the critical need for better biomarker testing to optimize treatment sequencing and patient selection in an increasingly complex therapeutic landscape.
Beth N. McLellan, MD
Latest:
Dr McLellan on the Association Between A Skin Bacterium and Severe Acute Radiation Dermatitis
Beth N. McLellan, MD, discusses the use of a low-cost, topical treatment to prevent severe cases of acute radiation dermatitis potentially caused by the skin bacterium Staphylococcus aureus in breast cancer.
Millie Das, MD
Millie Das, MD, is a clinical professor of medicine – oncology in the Department of Medicine at Stanford University; a member of the Stanford Cancer Institute; and chief of Oncology at the VA Palo Alto Health Care System
Latest:
Dr Das on Updates to the Standard First-Line Treatment Paradigm for ES-SCLC
Millie Das, MD, discusses first-line standards of care for patients with extensive-stage and limited-stage small cell lung cancer.
Judith Karp, MD
Latest:
Women in Oncology: Leukemia Therapies in Humans, for Humans
Judith Karp, MD, Azra Raza, MD, and Michelle M. Le Beau, PhD, discuss their proudest career accomplishments, including the investigation of potential treatments using a patient’s first cancerous cell, advances in cytogenetics, and a rational design for clinical trials involving cell cytokinetics..
Suzanne Mahon DNS, RN, AOCN, AGN-BC, FAAN
Suzanne Mahon, DNS, RN, AOCN®, AGN-BC, FAAN, is a professor emeritus at Saint Louis University in Missouri.
Latest:
Dr Mahon on the Importance of Integrating Genomic Science Into Oncology Practice
Suzanne Mahon DNS, RN, AOCN, AGN-BC, FAAN, discusses the importance of integrating genomic science into oncology practice.
Huiqiang Huang, MD, PhD
Huiqiang Huang, MD, PhD, is a professor and deputy director of the Medical Oncology Department at Sun Yat-sen University Cancer Center in Guangzhou, China.
Latest:
Dr Huang on the Efficacy of Sintilimab Plus Chidamide and P-GemOx in Treatment-Naive ENKTL.
Ajai Chari, MD, highlighted key areas of debate in smoldering myeloma from the Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Conference.